Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years

被引：0
|
作者：
Meyer, Ulrike
Zehnter, Elmar
Mauss, Stefan
Boeker, Klaus
Lutz, Thomas
Racky, Stefan
Schmidt, Wolfgang
Ullrich, Rainer
Sbrijer, Innessa
Heyne, Renate
Schober, Andreas
John, Christine
Hey, Karl-Heinz
Bokemeyer, Bernd
Kallinowski, Birgit
Moeller, Bernd
Pape, Stefan
Alshuth, Ulrich
Hueppe, Dietrich
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A790 / A791
页数：2
相关论文
共 50 条
  • [1] Predictive factors in treatment of chronic hepatitis c (cHC) patients with peginterferon alfa-2a (40KD) and ribavirin
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Berrid
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A839 - A839
  • [2] Differences between genotype 1 patients with SVR or relapse after treatment for chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV)
    Zehnter, Elmar
    Mauss, Stefan
    Beoker, Klaus
    Thomas, Lutz
    Racky, Stefan
    Schmidt, Wolfgang
    Ullrich, Rainer
    Sbrijer, Innessa
    Heyne, Renate
    Schober, Andreas
    John, Christine
    Hey, Karl-Heinz
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Moeller, Bernd
    Pape, Stefan
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2007, 132 (04) : A789 - A789
  • [3] PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
    Mauss, S.
    Schober, A.
    Lutz, T.
    Moog, G.
    Schuchmann, M.
    Heyne, R.
    John, C.
    Schiffelholz, W.
    Baumgarten, A.
    Hey, K. -H.
    Eisenbach, C.
    Teuber, G.
    Schmidt, W.
    Bruch, H. -R.
    Geyer, P.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S185 - S185
  • [4] Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
    Mauss, Stefan
    Schober, Andreas
    Lutz, Thomas
    Moog, Gero
    Schuchmann, Marcus
    Heyne, Renate
    John, Christine
    Schiffelholz, Willibold
    Baumgarten, Axel
    Hey, Karl-Heinz
    Eisenbach, Christoph
    Teuber, Gerlinde
    Schmidt, Wolfgang
    Bruch, Harald-Robert
    Geyer, Peter
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [5] PEG-IFN alfa-2a (40KD) (PEGASYS®) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC).
    Ideo, G
    Antonucci, G
    Attili, AF
    Babudieri, S
    Chirianni, A
    Craxì, A
    Di Perri, G
    Francavilla, A
    Mangia, A
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Suter, F
    Tripi, S
    Sarracino, M
    HEPATOLOGY, 2003, 38 (04) : 728A - 728A
  • [6] PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC)
    Ideo, G
    Attili, A
    Ruggiero, G
    Craxi, A
    Di Perri, G
    Mangia, A
    Picciotto, A
    Rizzetto, M
    Suter, F
    Sarracino, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 146 - 146
  • [7] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
  • [8] Safety and adherence to peginterferon alfa-2a (40KD) plus ribavirin (RBV) in black Americans with chronic hepatitis C (CHC) HCV genotype 1
    Howell, CD
    Jeffers, LS
    Hu, S
    Lopez-Talavera, JC
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A723
  • [9] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [10] Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions
    Hueppe, Dietrich
    Zehnter, Elmar
    Mauss, Stefan
    Kaiser, Stephan
    Schober, Andreas
    Schuchmann, Marcus
    Boeker, Klaus
    Moog, Gero
    Schiffelholz, Willibold
    Pape, Stefan
    Heyne, Renate
    Ackermann, Frank
    Schmidt, Wolfgang
    John, Christine
    Lohmeyer, Juergen
    Hey, Karl-Heinz
    Alshuth, Ulrich
    GASTROENTEROLOGY, 2009, 136 (05) : A839 - A840
12345